UCT is an emerging biotechnology company that has developed a sensitive cancer test that can reliably measure the amount of N-glycoprotein CA-62 biomarker in the subject’s sample from a routine blood draw. The test can detect the majority of cancer types at all stages (stage I through IV), even before a subject may become symptomatic. Because of its non-invasive approach and rapid turnaround time UCT’s CA-62 biomarker test can also be used to monitor the success of ongoing cancer treatments as well as identify relapses in remission patients.
UCT was formed based on a unique history of research surrounding CA-62 protein receptors. The CA-62 receptors, found on the surface of epithelial cancer cells, can be detected and quantified from a single blood draw with high levels of specificity and sensitivity. The team at UCT has developed a robust test kit, confirmed by results from over 10,000 human samples.
Cancer is one of the most widespread diseases in the world. It touches most of us, whether it be directly, or through loved ones and friends. Cancer is one of the leading causes of death around the world. One in six deaths or 9.6 million die from cancer annually and millions more are diagnosed with cancer at some time in their lives.
Healthcare costs for advanced cancer treatments continue to increase. Cancer can destroy the patient’s ability to work, function or enjoy life while struggling with expensive and debilitating treatment regimens. Cancer can ultimately mean lost time with loved ones. Detecting cancer early can reduce these impacts significantly.
There are currently no widely available cancer tests on the market that can detect most types of epithelial cancer in the early stages of the disease. Many types of cancer are detected today through a combination of blood tests, imaging methods and invasive physical surgical exams. These conventional methods tend to be costly, time consuming and result in a high rate of false positives. As a result, most cancer cases are detected in later stages (III or IV), when survivability rates decrease greatly.
Being able to reliably detect cancer at the earliest stages allows oncologists to begin treatment programs that have a much greater rate of success in extending patient life and treating cancer to remission.
As cancer is one of the leading causes of death around the world, finding a better technology to detect cancer early, is more important than ever.
UCT is managed by a team of dedicated international scientists and professionals, focused on the single goal of saving lives by accelerating the detection of cancer.
Viatcheslav Kondratiev, M.SC., MBA | Chief Executive Officer
Canada
Mr. Kondratiev is an entrepreneur with a record of success in drug and medical device development.
Dr. Jannetta Tcherkassova, Ph.D. CRC | Head of In-Vitro Diagnostics
Canada
Dr. Tcherkassova has an extensive scientific knowledge and over 15 years of experience in in-vitro diagnostics of cancer, both in Canada and internationally.
Evgueni Klinski, Ph.D. | Senior Scientist
Canada
Dr. Klinski_has over 25 years of broad experience in in-vitro diagnostics, protein purification, and anti-cancer drug development in the Canadian pharmaceutical industry.
Dr. Joel Goodman, Ph.D.| Director of Lab Operations
Canada
Mr. Goodman is a former VP of Innovations and Development at Dynacare/LabCorp. With nearly 30 years at Dynacare, he served as Chief Science Officer (both in Canada and the USA) and Laboratory Director.
Ricardo Moro, M.D. | Scientific Advisor
Canada
Dr. Moro is a member of the editorial board of the scientific journal Tumor Biology, and the Canadian President of the International Society of Oncology and Biomarkers (ISOBM). He has over 40 years of experience in biomedicine, immunology, in-vitro cancer diagnostics, and the design of medical tests and devices.
Stéphane Gagné, MBA | Business Advisor
Canada
Mr. Gagne brings over 20 years of experience in pharmaceutical oncology, cosmetics, and nutritional supplements to his advisory role at UCT. He has held senior leadership positions at Ovensa Inc., Radient Technologies Inc., Aeterna Laboratories, and Atrium Innovations.
Vera Gorbunova, M.D. | Medical Advisor
Russia
Dr. Gorbunova is a leading researcher and chemotherapist specializing in tumor diseases and chemotherapy. She conducts Phase I-III clinical studies, has published over 800 papers and 20 monographs, and is actively involved in major oncology associations. She also chairs expert groups on cancer drug treatments.
Boris Brizeli, FSA, FCIA | Business Advisor
Canada
Mr. Brizeli has over 35 years of experience as a strategic advisor to major insurers and as a successful venture investor.
Dr. Berz, MD, PhD, MPH | Business Advisor
USA
Dr. Berz is a practicing oncologist specializing in cancer-immune therapies and personalized therapeutics. He is a thought leader and prolific researcher in early cancer detection and leads several cancer research investigational trials.